All sponsors

TYK Medicines, Inc

Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS7
PHASE 3 / 2-31
RECRUITING3
READOUTS ≤12 MONTHS1
READOUT SLIPPED >6 MO0%

Delay Index: of 5 active trials registered more than a year ago, 0 have moved their primary completion (readout) date by more than 6 months since first registration (median +0.0 months). See all sponsors →

Open TYK Medicines, Inc on the live radar map →
TRIALPHASESTATUSCONDITIONNPRIMARY COMPLETION
TY-9591
NCT05382728
P3RecruitingNSCLC; EGFR Activating Mutation6802025-05
TY-9591
NCT05948813
P2RecruitingNSCLC; EGFR Activating Mutation4202025-12-15 (+6 mo)
TYK-00540
NCT06950086
P1/2RecruitingHR-positive, HER2-negative Advanced Breast Cancer1802026-09
TY-302
NCT07104617
P1/2Not yet recruitingMetastatic Castration-resistant Prostate Cancer (mCRPC)482026-10
TYK-00540
NCT07104643
P1/2Not yet recruitingmCRPC482026-11
TY-9591 80mg QD+pemetrexed+Cisplatin/Carboplatin
NCT06672068
P2Not yet recruitingNSCLC602027-12-01
TYK-01054
NCT07282873
P1/2Not yet recruitingSolid Tumor Malignancies; Malignant Mesothelioma (MM)2192028-01